ES2139097T3 - Agente de contraste. - Google Patents

Agente de contraste.

Info

Publication number
ES2139097T3
ES2139097T3 ES94927724T ES94927724T ES2139097T3 ES 2139097 T3 ES2139097 T3 ES 2139097T3 ES 94927724 T ES94927724 T ES 94927724T ES 94927724 T ES94927724 T ES 94927724T ES 2139097 T3 ES2139097 T3 ES 2139097T3
Authority
ES
Spain
Prior art keywords
contrast agents
contrast agent
particulate
polyaminoacids
particulate contrast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94927724T
Other languages
English (en)
Inventor
Anne Kjersti Fahlvik
Anne Naevestad
Helge Gundersen
Per Strande
Jo Klaveness
Anne Jacobsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26304264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2139097(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nycomed Imaging AS filed Critical Nycomed Imaging AS
Application granted granted Critical
Publication of ES2139097T3 publication Critical patent/ES2139097T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1258—Pills, tablets, lozenges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1854—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A61K49/1872—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid coated or functionalised with a polyamino acid, e.g. polylysine, polyglutamic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Hard Magnetic Materials (AREA)
  • Soft Magnetic Materials (AREA)

Abstract

LA INVENCION SE REFIERE A AGENTES DE CONTRASTE PARTICULADOS, ESPECIALMENTE AGENTES DE CONTRASTE PARA LA VISUALIZACION MR, QUE TIENEN UN OXIDO DE METAL, PREFERIBLEMENTE UN NUCLEO DE OXIDO DE HIERRO SUPERMAGNETICO SUMINISTRADO CON UNA BAJA DENSIDAD DE COBERTURA DE UN AGENTE DE COBERTURA DE POLIELECTROLITOS SELECCIONADOS A PARTIR DE POLISACARIDOS Y POLIMEROS SINTETICOS, ESPECIALMENTE POLIAMINOACIDOS. A DIFERENCIA DE PARTICULADOS RECUBIERTOS CONVENCIONALES, LAS NUEVAS PARTICULAS TIENEN UN EFECTO REDUCIDO O BIEN NO TIENEN NINGUN EFECTO EN LOS PARAMETROS CARDIOVASCULARES, DISMINUCION PLAQUETARIA, ACTIVACION COMPLEMENTARIA Y COAGULACION SANGUINEA.
ES94927724T 1994-09-27 1994-09-27 Agente de contraste. Expired - Lifetime ES2139097T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB1994/002097 WO1996009840A1 (en) 1994-09-27 1994-09-27 Contrast agent
US09/243,437 US6207134B1 (en) 1994-09-27 1999-02-03 Ultrafine lightly coated superparamagnetic particles for MRI

Publications (1)

Publication Number Publication Date
ES2139097T3 true ES2139097T3 (es) 2000-02-01

Family

ID=26304264

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94927724T Expired - Lifetime ES2139097T3 (es) 1994-09-27 1994-09-27 Agente de contraste.

Country Status (11)

Country Link
US (1) US6207134B1 (es)
EP (1) EP0783325B2 (es)
JP (1) JPH10506121A (es)
AT (1) ATE187079T1 (es)
AU (1) AU687093B2 (es)
DE (1) DE69421943T2 (es)
DK (1) DK0783325T3 (es)
ES (1) ES2139097T3 (es)
NO (1) NO971436L (es)
RU (1) RU2147243C1 (es)
WO (1) WO1996009840A1 (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT81498B (pt) * 1984-11-23 1987-12-30 Schering Ag Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas
AU716667B2 (en) 1996-01-10 2000-03-02 Nycomed Imaging As Contrast media
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
DE19612001A1 (de) * 1996-03-18 1997-09-25 Silica Gel Gmbh Adsorptions Te Superparamagnetische Teilchen mit vergrößerter R¶1¶-Relaxivität, Verfahren zur Herstellung und deren Verwendung
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
JP3662347B2 (ja) * 1996-06-10 2005-06-22 日鉄鉱業株式会社 医療用粉体
AU727764B2 (en) * 1996-08-05 2000-12-21 Schering Aktiengesellschaft Process for the production of contrast media for magnetic resonance tomography
DE19721947C2 (de) * 1997-05-21 1999-04-22 Diagnostikforschung Inst Verwendung von pharmazeutischen Zubereitungen, die Partikel, Vesikel oder Polymere sowie nichtsteroidale Antirheumatika und/oder Thrombozytenaggregationshemmer zur Darstellung der Gefäße, Lymphknoten und des Knochenmarks enthalten
WO1999052564A1 (en) * 1998-04-09 1999-10-21 Nycomed Imaging A.S Method
DK1169062T3 (da) 1999-04-09 2010-01-25 Amag Pharmaceuticals Inc Varmestabile overtrukne kolloide jernoxider
EP1522318A3 (en) * 1999-04-09 2005-07-06 Advanced Magnetics Incorporated Heat stable coated colloidal iron oxides
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
WO2001074406A2 (en) * 2000-03-31 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Dendrimer composition for magnetic resonance analysis
WO2001082899A2 (en) * 2000-05-03 2001-11-08 Mbt Munich Biotechnology Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US7445619B2 (en) * 2000-08-18 2008-11-04 Map Technologies Llc Devices for electrosurgery
US20040167244A1 (en) * 2000-08-18 2004-08-26 Auge Wayne K. Methods and compositions for fusing bone during endoscopy procedures
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6549798B2 (en) 2001-02-07 2003-04-15 Epix Medical, Inc. Magnetic resonance angiography data
DE10108857A1 (de) * 2001-02-14 2002-09-19 Hans-Dieter Hunger Bioaktive und biokompatible Konjugate mit magnetischen Eigenschaften und Verfahren zu deren Herstellung
US7066932B1 (en) * 2001-05-26 2006-06-27 Map Technologies Llc Biologically enhanced irrigants
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US8734441B2 (en) * 2001-08-15 2014-05-27 Nuortho Surgical, Inc. Interfacing media manipulation with non-ablation radiofrequency energy system and method
US8591508B2 (en) * 2001-08-15 2013-11-26 Nuortho Surgical, Inc. Electrosurgical plenum
US8235979B2 (en) * 2001-08-15 2012-08-07 Nuortho Surgical, Inc. Interfacing media manipulation with non-ablation radiofrequency energy system and method
MXPA04002446A (es) * 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030100830A1 (en) * 2001-11-27 2003-05-29 Sheng-Ping Zhong Implantable or insertable medical devices visible under magnetic resonance imaging
US20040143180A1 (en) * 2001-11-27 2004-07-22 Sheng-Ping Zhong Medical devices visible under magnetic resonance imaging
US20030185757A1 (en) * 2002-03-27 2003-10-02 Mayk Kresse Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
WO2003082547A1 (en) * 2002-03-28 2003-10-09 Scimed Life Systems, Inc. Polymer welding using ferromagnetic particles
US7163655B2 (en) * 2002-03-28 2007-01-16 Scimed Life Systems, Inc. Method and apparatus for extruding polymers employing microwave energy
US6979420B2 (en) * 2002-03-28 2005-12-27 Scimed Life Systems, Inc. Method of molding balloon catheters employing microwave energy
US6962685B2 (en) * 2002-04-17 2005-11-08 International Business Machines Corporation Synthesis of magnetite nanoparticles and the process of forming Fe-based nanomaterials
US8862203B2 (en) * 2003-03-27 2014-10-14 Boston Scientific Scimed Inc. Medical device with temperature modulator for use in magnetic resonance imaging
US20050261763A1 (en) * 2003-04-08 2005-11-24 Xingwu Wang Medical device
US20050244337A1 (en) * 2003-04-08 2005-11-03 Xingwu Wang Medical device with a marker
US20050240100A1 (en) * 2003-04-08 2005-10-27 Xingwu Wang MRI imageable medical device
US20050278020A1 (en) * 2003-04-08 2005-12-15 Xingwu Wang Medical device
GB0313259D0 (en) * 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
US20060239913A1 (en) * 2003-06-25 2006-10-26 Marc Port Peptide conjugate for magnetic resonance imaging
US20050014851A1 (en) * 2003-07-18 2005-01-20 Eastman Kodak Company Colloidal core-shell assemblies and methods of preparation
US20070031339A1 (en) * 2003-11-28 2007-02-08 Oskar Axelsson Contrast agents
US20050152842A1 (en) * 2003-12-24 2005-07-14 Chun Li Poly (L-glutamic acid) paramagnetic material complex and use as a biodegradable MRI contrast agent
US8620406B2 (en) * 2004-01-23 2013-12-31 Boston Scientific Scimed, Inc. Medical devices visible by magnetic resonance imaging
US20050196416A1 (en) * 2004-02-05 2005-09-08 Kipp James E. Dispersions prepared by use of self-stabilizing agents
US7761138B2 (en) * 2004-03-12 2010-07-20 Boston Scientific Scimed, Inc. MRI and X-ray visualization
US7483732B2 (en) * 2004-04-15 2009-01-27 Boston Scientific Scimed, Inc. Magnetic resonance imaging of a medical device and proximate body tissue
DE102004052533A1 (de) * 2004-10-15 2006-05-04 Mykhaylyk, Olga, Dr. Magnetische Partikel zur Verwendung in Therapie und Diagnostik
DE102004054536A1 (de) * 2004-11-06 2006-05-11 Capsulution Nanoscience Ag Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel
US20060140867A1 (en) * 2004-12-28 2006-06-29 Helfer Jeffrey L Coated stent assembly and coating materials
US20060293396A1 (en) * 2005-01-14 2006-12-28 Eastman Kodak Company Amine polymer-modified nanoparticulate carriers
KR20080009682A (ko) * 2005-04-01 2008-01-29 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 킬레이트제인 폴리(펩티드): 제조 방법과 용도
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
US20070237821A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Nanogel-based contrast agents for optical molecular imaging
EP1738773A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzung und deren Vervendung in bildgebenden Verfahren
US7778684B2 (en) * 2005-08-08 2010-08-17 Boston Scientific Scimed, Inc. MRI resonator system with stent implant
US20080095699A1 (en) * 2006-10-20 2008-04-24 Shiying Zheng Imaging contrast agents using nanoparticles
DE102005053618A1 (de) * 2005-11-10 2007-05-16 Merck Patent Gmbh Nanoskalige Partikel als Kontrastmittel für die Kernspintomographie
US20070134341A1 (en) * 2005-11-15 2007-06-14 Kipp James E Compositions of lipoxygenase inhibitors
EP1991577A2 (en) 2006-01-31 2008-11-19 Parkinson, John F. Modulation of mdl-1 activity for treatment of inflammatory disease
US20070239256A1 (en) * 2006-03-22 2007-10-11 Jan Weber Medical devices having electrical circuits with multilayer regions
US20070258907A1 (en) * 2006-04-24 2007-11-08 Davis Mark E Polymer-coated paramagnetic particles
US20080014285A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound
US7892520B2 (en) * 2006-07-31 2011-02-22 The Hong Kong University Of Science And Technology Solid-state synthesis of iron oxide nanoparticles
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
GB0820309D0 (en) * 2008-11-06 2008-12-17 Middlesex University Higher Ed Detection of cancer
US8574549B2 (en) * 2008-12-29 2013-11-05 General Electric Company Nanoparticle contrast agents for diagnostic imaging
US9399075B2 (en) 2008-12-29 2016-07-26 General Electric Company Nanoparticle contrast agents for diagnostic imaging
CN101474414B (zh) * 2009-02-06 2010-09-15 上海师范大学 高分子包裹磁性纳米粒子造影剂的制备及应用
US9532827B2 (en) 2009-06-17 2017-01-03 Nuortho Surgical Inc. Connection of a bipolar electrosurgical hand piece to a monopolar output of an electrosurgical generator
US9408658B2 (en) 2011-02-24 2016-08-09 Nuortho Surgical, Inc. System and method for a physiochemical scalpel to eliminate biologic tissue over-resection and induce tissue healing
RU2453270C1 (ru) * 2011-03-31 2012-06-20 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения и социального развития Российской Федерации" (ФГУ "МНИОИ им. П.А. Герцена" Минздравсоцразвития России) Способ исследования терминального отдела толстой кишки
KR101398214B1 (ko) * 2011-04-06 2014-05-23 주식회사 바이오리더스 음이온성 고분자와 양이온성 고분자 이온복합체 기반 고감도 자기공명영상 나노조영제 및 이의 제조방법
RU2465010C1 (ru) * 2011-06-08 2012-10-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Контрастное средство для магнитно-резонансной томографии
WO2013110828A1 (es) * 2012-01-27 2013-08-01 Soluciones Nanotecnológicas, S.L. Nanopartículas su perparamagn éticas como agente de contraste para imagen por resonancia magnética (irm) de la susceptibilidad magnética (t2*)
CZ304654B6 (cs) 2012-11-27 2014-08-20 Contipro Biotech S.R.O. Nanomicelární kompozice na bázi C6-C18-acylovaného hyaluronanu, způsob přípravy C6-C18-acylovaného hyaluronanu, způsob přípravy nanomicelární kompozice a stabilizované nanomicelární kompozice a použití
US9579142B1 (en) 2012-12-13 2017-02-28 Nuortho Surgical Inc. Multi-function RF-probe with dual electrode positioning
CA2902209A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CZ305153B6 (cs) 2014-03-11 2015-05-20 Contipro Biotech S.R.O. Konjugáty oligomeru kyseliny hyaluronové nebo její soli, způsob jejich přípravy a použití
US9597418B2 (en) * 2014-03-18 2017-03-21 Universite De Nantes Magnetic and fluorescent reverse nanoassemblies
CZ2014451A3 (cs) * 2014-06-30 2016-01-13 Contipro Pharma A.S. Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití
CZ309295B6 (cs) 2015-03-09 2022-08-10 Contipro A.S. Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití
CZ2015398A3 (cs) 2015-06-15 2017-02-08 Contipro A.S. Způsob síťování polysacharidů s využitím fotolabilních chránicích skupin
CZ306662B6 (cs) 2015-06-26 2017-04-26 Contipro A.S. Deriváty sulfatovaných polysacharidů, způsob jejich přípravy, způsob jejich modifikace a použití
JP6879670B2 (ja) * 2016-03-30 2021-06-02 小林製薬株式会社 シワ及び／又は毛穴の隠蔽用の外用組成物
CZ308106B6 (cs) 2016-06-27 2020-01-08 Contipro A.S. Nenasycené deriváty polysacharidů, způsob jejich přípravy a jejich použití
EP3412303A1 (en) 2017-06-08 2018-12-12 Medizinische Universität Innsbruck Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
WO2020053204A1 (en) 2018-09-10 2020-03-19 Saving Patients' Lives Medical B.V. Ultra-small superparamagnetic iron oxide nanoparticles

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5746999A (en) * 1984-11-23 1998-05-05 Schering Aktiengesellschaft Magnetic particles for diagnostic purposes
US5597531A (en) † 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
US5314679A (en) * 1986-07-03 1994-05-24 Advanced Magnetics Inc. Vascular magnetic resonance imaging agent comprising nanoparticles
US4827945A (en) † 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5679323A (en) * 1986-07-03 1997-10-21 Advanced Magnetics, Inc. Hepatocyte-specific receptor-mediated endocytosis-type compositions
US5055288A (en) * 1987-06-26 1991-10-08 Advanced Magnetics, Inc. Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
US5284646A (en) * 1986-07-03 1994-02-08 Advanced Magnetics Inc. Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5262176A (en) † 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
WO1990015666A1 (en) † 1989-06-16 1990-12-27 Omni Quest Corporation Coated magnetic particles for use in separations
JP2726520B2 (ja) * 1989-10-20 1998-03-11 名糖産業株式会社 有機磁性複合体
EP0526503B1 (en) * 1990-04-10 1997-06-04 Imarx Pharmaceutical Corp. Polymers as contrast media for magnetic resonance imaging
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
DE4117782C2 (de) † 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
EP0543020B1 (en) * 1991-06-11 1997-12-29 Meito Sangyo Kabushiki Kaisha Oxidized composite comprising water-soluble carboxypolysaccharide and magnetic iron oxide
US5225282A (en) * 1991-12-13 1993-07-06 Molecular Bioquest, Inc. Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer
ATE132758T1 (de) * 1992-06-01 1996-01-15 Basf Ag Anwendung von dispersionen von magneto-ionischen partikeln in mri-kontrast-mitteln
ES2130406T5 (es) * 1992-08-05 2003-12-16 Meito Sangyo Kk Material compuesto de pequeño diametro compuesto de carboxipolisacarido soluble en agua y oxido de hierro magnetico.
US5411730A (en) * 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles

Also Published As

Publication number Publication date
AU687093B2 (en) 1998-02-19
ATE187079T1 (de) 1999-12-15
EP0783325A1 (en) 1997-07-16
AU7702994A (en) 1996-04-19
NO971436D0 (no) 1997-03-25
WO1996009840A1 (en) 1996-04-04
DE69421943T2 (de) 2000-05-18
EP0783325B1 (en) 1999-12-01
US6207134B1 (en) 2001-03-27
DK0783325T3 (da) 2000-05-01
EP0783325B2 (en) 2004-03-31
NO971436L (no) 1997-05-23
RU2147243C1 (ru) 2000-04-10
DE69421943D1 (de) 2000-01-05
JPH10506121A (ja) 1998-06-16

Similar Documents

Publication Publication Date Title
ES2139097T3 (es) Agente de contraste.
EA199800630A1 (ru) Контрастное вещество
EP0600529A3 (en) Preparation and magnetic properties of very small magnetite-dextran particles.
IL114713A (en) Iron-containing nanoparticles methods for the production thereof and use thereof as contrast media
IE46009L (en) Superficially porous macroparticles
DE69530151D1 (de) Magnetlegierung und seiner Herstellungsverfahren
DE69926533D1 (de) Partikel
ITMI910038A0 (it) Dispositivo indicatore dello stato di usura degli elementi d'attrito dei freni
ATE83686T1 (de) Zur selektiven abtrennung von metallkationen aus waessrigen loesungen geeignetes teilchenfoermiges mittel, verfahren zu seiner herstellung und seine verwendung.
UA42698C2 (uk) Нитка, що включає принаймні один ниткоподібний елемент, з`єднання ниток, каталізатори, пристрій, призначений для рекуперації частинок дорогоцінних металів або їх сплавів, пристрій, призначений для уловлювання частинок дорогоцінних металів або їх сплавів
DE69203540D1 (de) Faseriges Metallhydroxydverbundmaterial und Verfahren zu seiner Herstellung.
DE69522774D1 (de) Poröser Metallkörper und Verfahren seiner Herstellung
GB2280452B (en) Wear-resistant high permeability magnetic alloy and method of manufacturing the same
FR2587989B1 (fr) Compositions particulaires d'oxalates de metaux ferromagnetiques, sous forme de particules aciculaires submicroniques, leur preparation et leur application
DE69513432D1 (de) Legierungsstahlpulver, Sinterkörper und Verfahren
EP1109929A4 (en) METHOD FOR THE DIAGNOSIS OF DEGREE OF SALMON SYNDROME AND ALZHEIMER'S DISEASE AND TREATMENT METHOD
DE69527304D1 (de) Ferrofluid mit verbesserter oxidationsbeständigkheit
MX9603619A (es) Microparticulas que contienen gas, medios que contienen el ultimo, su uso en diagnosis ultrasonica, tambien como procesos para la produccion de las particulas y los medios.
ATE132758T1 (de) Anwendung von dispersionen von magneto-ionischen partikeln in mri-kontrast-mitteln
DE69717269D1 (de) T1-zeitgewichteten kernspintomogram der res-orgäne
DE3788111D1 (de) Plättchenförmige Ferritteilchen vom Magnetoplumbittyp für magnetische Aufzeichnung und Verfahren zur Herstellung derselben.
DE59500393D1 (de) Verfahren zur Herstellung von Cyclopropylalkylketonen und 4,5-Dihydroalkylfuranen
DE69027201D1 (de) Korrosionsbeständiger magnet vom tm-b-re-typ und dessen herstellungsverfahren
ID27976A (id) 4,5,6 dan 7-indol dan turunan-turunan indolin, pembuatan dan penggunaannya
BR9106760A (pt) Agente de dois componentes para a coagulacao de lacas,ceras e agentes de revestimento

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 783325

Country of ref document: ES